22 May 2013 - 22 May 2013 - US CytRx Corp (NASDAQ:CYTR) unveiled on Tuesday initial findings from a Phase Ib study of its conjugate of the chemotherapeutic agent doxorubicin, aldoxorubicin, in solid tumours.

Data from the study involving patients with metastatic solid tumours who have either relapsed or not responded to treatment with standard therapies showed that aldoxorubicin has a distribution half-life of 20-24 hours following infusion, which is substantially longer than doxorubicin's initial half-life of five minutes. The results also demonstrate that aldoxorubicin showed a distribution to healthy tissues that was 250-fold lower than that of doxorubicin.

CytRx's president and chief executive Steven Kriegsman commented that aldoxorubicin could be active against a variety of cancers, having shown to be superior to widely used doxorubicin in multiple animal models of cancer.